Skip to content

Randomized Investigation of Chest Pain Diagnostic Strategies

Randomized Investigation of Chest Pain Diagnostic Strategies

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01035047
Enrollment
105
Registered
2009-12-18
Start date
2010-01-31
Completion date
2012-08-31
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Chest Pain

Keywords

Acute Coronary Syndrome, Chest pain, Cardiac MRI, Risk Stratification, Emergency Department

Brief summary

Clinical decision units (CDUs) improve resource utilization and are a recommended care option by the American College of Cardiology / American Heart Association, but are underutilized in non-low risk chest pain patients due to weaknesses of traditional cardiac testing. Cardiac magnetic resonance imaging (CMR) is sensitive and specific for ischemia, can simultaneously assess cardiac function and myocardial perfusion, and could revolutionize the diagnostic process for intermediate risk patients with chest pain. The primary objective of this trial is to measure the efficiency and safety of a combined CDU-CMR care pathway compared to inpatient care among patients with non-low risk acute chest pain.

Detailed description

Despite spending $12 billion annually on the emergency evaluation of chest pain in the US, only 15% of admitted patients have a cardiac cause of their presenting symptoms. Clinical decision units (CDUs) improve resource utilization and are a recommended care option by the American College of Cardiology / American Heart Association, but are underutilized in non-low risk chest pain patients due to weaknesses of traditional cardiac testing. Cardiac magnetic resonance imaging (CMR) is sensitive and specific for ischemia, can simultaneously assess cardiac function and myocardial perfusion, and could revolutionize the diagnostic process for intermediate risk patients with chest pain. The superior accuracy of CMR could decrease testing and invasive procedures. The high sensitivity for ongoing ischemia could allow imaging in parallel with cardiac markers. As a result, CMR could improve the care of emergency department (ED) patients with intermediate risk chest pain. However, the efficiency and safety of CMR has not been extensively tested in the CDU setting. Primary Hypothesis: A CDU-CMR strategy will reduce the occurrence of the composite of revascularization, re-hospitalization, and recurrent cardiac testing at 90 days when compared to an inpatient care strategy. Methods: Participants (n=146) at intermediate risk for acute coronary syndrome (ACS) will be recruited into a clinical trial from Wake Forest University Baptist Medical Center (WFUBMC) ED. Participants will be equally randomized to CDU-CMR or inpatient care. CDU-CMR participants will undergo resting and stress CMR imaging in parallel with serial cardiac markers. Inpatient care participants will undergo serial cardiac markers followed by existing cardiac testing as determined by their care providers. The primary outcome is the composite of 90 day revascularization, re-hospitalization, and recurrent cardiac testing. The secondary outcome is index hospitalization length of stay. Safety events include ACS after discharge, mortality, and stress testing-related adverse events.

Interventions

OTHERClinical decision unit care, coupled with cardiac MRI

After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age greater than or equal to 21 years of age at the time of enrollment * Chest discomfort or other symptoms consistent with possible ACS as indicated by the treating physician after obtaining an ECG and cardiac biomarkers for the patient's evaluation * Thrombolysis in myocardial infarction (TIMI) risk score \>/= 2 or physician impression of intermediate or high likelihood symptoms represent ACS * Patient requires an inpatient or CDU evaluation for their chest pain * The treating physician feels the patient could be discharged home if cardiac disease was excluded * The treating physician feels the patient is safe for CDU care Pretest probability assessment The assessment of intermediate risk for developing ACS will be based on a TIMI risk score \>/= 2 and / or a board certified / board eligible emergency physician clinical impression of intermediate or high likelihood that the symptoms represent ACS. Physicians are encouraged to use the 2007 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines as a framework for this assessment.

Exclusion criteria

* Elevated cardiac biomarkers * New ST-segment elevation on any electrocardiogram (\>/= 1 mV) * New ST-segment depression on any electrocardiogram (\>/= 2 mV) * Known inducible cardiac ischemia without subsequent revascularization * Unable to lie flat * Symptomatic hypotension at the time of enrollment (systolic \< 90 mm Hg) * Contra-indications to MRI (examples: Pacemaker, defibrillator, cerebral aneurysm clips, metallic ocular foreign body, implanted devices, severe claustrophobia) * Patient refusal or inability to comply with medical record review and follow up * Terminal diagnosis with life expectancy less than 3 months * Currently Pregnant * Creatinine clearance \< 45 ml/min at the time of enrollment or clinical concern for acute kidney injury * Chronic liver disease with a creatinine clearance of \<60 ml/min at the time of enrollment * Hepato-renal syndrome * History of liver, heart, or kidney transplant * Confirmed angioplasty, stent placement, or coronary artery bypass grafting (CABG) within the last 6 months

Design outcomes

Primary

MeasureTime frame
The Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days.Index Hospitalization through 90 days

Secondary

MeasureTime frame
Length of StayDuration of Index Hospitalization, an average of 1-2 days
Acute Coronary SyndromeIndex Hospitalization discharge through 90 days
MortalityIndex Hospitalization through 90 days
Stress Testing-related Adverse EventIndex Hospitalization through 90 days

Countries

United States

Participant flow

Recruitment details

Recruitment occurred in the Emergency Department (ED) at Wake Forest Baptist Medical Center from March 2010 to June 2011.

Pre-assignment details

No participants were excluded from the trial prior to treatment assignment.

Participants by arm

ArmCount
CDU-CMR Protocol
Patients will be transferred to the clinical decision unit and undergo a stress cardiac MRI evaluation. Clinical decision unit care, coupled with cardiac MRI : After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
52
Inpatient Care
This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
53
Total105

Baseline characteristics

CharacteristicCDU-CMR ProtocolInpatient CareTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
9 Participants15 Participants24 Participants
Age, Categorical
Between 18 and 65 years
43 Participants38 Participants81 Participants
Age, Continuous54 years59 years56 years
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants0 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
50 Participants53 Participants103 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
20 Participants15 Participants35 Participants
Race (NIH/OMB)
More than one race
2 Participants0 Participants2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
30 Participants38 Participants68 Participants
Sex: Female, Male
Female
24 Participants24 Participants48 Participants
Sex: Female, Male
Male
28 Participants29 Participants57 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
18 / 5217 / 53
serious
Total, serious adverse events
14 / 5215 / 53

Outcome results

Primary

The Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days.

Time frame: Index Hospitalization through 90 days

Population: Data from all participants was used in the primary outcome analysis.

ArmMeasureValue (NUMBER)
CDU-CMR ProtocolThe Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days.7 participants
Inpatient CareThe Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days.20 participants
Secondary

Acute Coronary Syndrome

Time frame: Index Hospitalization discharge through 90 days

Population: Data from all participants was used in outcome analysis.

ArmMeasureValue (NUMBER)
CDU-CMR ProtocolAcute Coronary Syndrome0 participants
Inpatient CareAcute Coronary Syndrome3 participants
Secondary

Length of Stay

Time frame: Duration of Index Hospitalization, an average of 1-2 days

Population: Data from all participants was used in outcome analysis.

ArmMeasureValue (MEDIAN)
CDU-CMR ProtocolLength of Stay21.1 hours
Inpatient CareLength of Stay26.3 hours
Secondary

Mortality

Time frame: Index Hospitalization through 90 days

Population: Data from all participants was used for outcome analysis.

ArmMeasureValue (NUMBER)
CDU-CMR ProtocolMortality0 participants
Inpatient CareMortality0 participants
Secondary

Stress Testing-related Adverse Event

Time frame: Index Hospitalization through 90 days

Population: Data from all participants was used for outcome analysis

ArmMeasureValue (NUMBER)
CDU-CMR ProtocolStress Testing-related Adverse Event1 participants
Inpatient CareStress Testing-related Adverse Event0 participants

Source: ClinicalTrials.gov · Data processed: Mar 23, 2026